Progressively, recent studies are identifying subtype-specific unique and viable therapeutic vulnerabilities for SCLC; for example, NOTCH activation, inhibition of AURKA/B, LSD1, HDAC, BET, and EZH2 [63–67]. This evidence concerns the gene HDAC9 and small cell lung carcinoma.